Objective: The aim of this study was to identify baseline peripheral blood biomarkers associated with clinical outcome in patients with NSCLC treated with nivolumab.
Introduction
Targeting of the immune system has been found to confer clinical benefit for patients with some types of advanced solid tumor. Nivolumab, a monoclonal antibody to the immune checkpoint protein programmed death 1 (PD-1), has been approved for the treatment of several solid tumor types including metastatic NSCLC. [1] [2] [3] [4] Given that only a limited number of patients experience a durable response whereas all those treated are at risk for specific immune side effects, the identification of individuals who are most likely to benefit from nivolumab and similar agents is an important clinical goal. Given the heterogeneity of the observed association between expression of the PD-1 ligand (PD-L1) on tumor cells and the clinical response to immune checkpoint inhibitors (ICIs), which is likely due in part to the difficulty in defining PD-L1 positivity and limited assay standardization, the establishment of reliable laboratory parameters predictive of the clinical outcome of ICI treatment in daily clinical practice is needed.
Although most immune therapies engage T cells, the immune response to cancer is a multistep process involving multiple cell subsets and soluble mediators that function at different times and at different sites. For instance, several blood-based parameters-including markers of systemic inflammation such as baseline absolute neutrophil count (ANC) and the neutrophil-tolymphocyte ratio-have been associated with survival in patients with melanoma treated with the ICI ipilimumab. [5] [6] [7] However, few studies have examined such potential markers for clinical outcome in patients with lung with cancer treated with ICIs. We have now examined the possible impact of clinical parameters determined in the routine laboratory setting-including peripheral blood cell counts such as ANC, absolute lymphocyte count (ALC), absolute monocyte count (AMC), and absolute eosinophil count (AEC)-on outcome in patients with advanced or recurrent NSCLC treated with nivolumab. Given that the serum concentration of C-reactive protein (CRP), a nonspecific marker of inflammation, has also been identified as an indicator of an immune response to tumor antigens 8 and that the serum level of lactate dehydrogenase (LDH) has been associated with outcome in patients with melanoma treated with the ICI pembrolizumab, 9 we also included CRP and LDH in our analysis. In addition, we investigated the impact of the level of PD-L1 expression in tumors, which has been identified as a biomarker for the response of patients with NSCLC to antibodies specific for PD-1 such as nivolumab and pembrolizumab. 10, 11 Our results suggest that a combination of peripheral blood parameters may prove useful for the stratification of patients with NSCLC according to the probability of their receiving benefit from nivolumab treatment.
Patients and Methods

Patients
We reviewed the medical records of all patients with advanced (stage IIIB to IV) or recurrent NSCLC who were treated with nivolumab at Kindai University Hospital, Kishiwada City Hospital, Izumi Municipal Hospital, or National Hospital Organization Osaka Minami Medical Center between December 2015 and August 2016. From this review, we identified a total of 139 patients with advanced NSCLC who were treated with nivolumab and for whom data for differential blood counts and serum levels of CRP and LDH determined within 7 days before the initiation of nivolumab treatment were available. Of these patients, 134 individuals were included in the analysis (see Supplementary Fig. 1 ). Nivolumab was administered intravenously at a dose of 3 mg/kg every 2 weeks. The end of the follow-up period was December 31, 2016. The study was performed according to protocols approved by the institutional review board of each participating hospital.
Data Collection
Data regarding clinicopathologic features and treatment history were extracted from the medical records review and were updated as of December 31, 2016. Tumor response was assessed by computed tomography every 6 to 8 weeks according to the Response Evaluation Criteria in Solid Tumors, version 1.1, 12 and was evaluable in 133 of the 134 patients enrolled in the study. Progression-free survival (PFS) was measured from the time of treatment initiation to clinical or radiographic progression or death from any cause. Overall survival (OS) was measured from the time of treatment initiation to death from any cause. Patients without documented clinical or radiographic disease progression or who were still alive were censored on the date of last follow-up. If exact dates were not known because the treating physician did not provide the appropriate information, the first day of the pertinent month was estimated as the date of disease progression or censoring. Precise dates related to nivolumab treatment were available for all patients.
PD-L1 Expression Analysis
Tumor biopsy specimens were subjected to immunohistochemical staining with a monoclonal antibody to PD-L1 (clone 28-8, Agilent Technologies, Santa Clara, CA) and with the use of an automated stainer (Dako Autostainer Link 48, Agilent Technologies). The stained slides were scanned with an Aperio CS2 scan scope (Leica Biosystems, Nussloch, Germany) and evaluated by board-certified pathologists who were blinded to clinical outcome. We defined PD-L1 positivity as membranous staining of tumor cells at any intensity with cutoffs of 1% or more and 50% or more of tumor cells in a section that included at least 100 evaluable tumor cells.
Statistical Analysis
The cutoff values for blood cell counts were 7500/mL for ANC, 5,13 1000/mL for ALC, 14, 15 650/mL for AMC, 16 and 150/mL for AEC. 9 The upper limit of the normal range served as the cutoff for serum levels of CRP and LDH. 6 Kaplan-Meier analysis of PFS and OS was performed on the basis of these cutoff values, with differences between each pair of groups being assessed with the log-rank test. The hazard ratio (HR) and 95% confidence interval (CI) were calculated with the univariable Cox proportional hazard model. Parameters with a p value less than 0.2 in the univariable analysis were selected for inclusion in multivariable analysis. Clinically important factors, including age (<75 versus 75 years), Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1 versus 2), smoking status (never versus former or current), and mutational status (positive for EGFR mutations sensitive to tyrosine kinase inhibitors [TKIs] or for the echinoderm microtubule associated protein like 4 gene [EML4]-ALK receptor tyrosine kinase gene [ALK] fusion gene versus negative for these gene alterations), were used as covariates in multivariable Cox proportional hazard regression analysis, the results of which were also expressed as HR and 95% CI. The relationship between best response and biomarker categories (groups A-C) was analyzed with Fisher's exact test. All statistical analysis was performed with the use of EZR (developed in 2012 by Y. Kanda, Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (version 2.13.0, R Foundation for Statistical Computing, Vienna, Austria). A p value less than 0.05 was considered statistically significant.
Results
Patient Characteristics
A total of 134 patients were included in the study. The clinical characteristics of these patients are summarized in Table 1 . All patients received nivolumab as second-line or later treatment. Of the 134 patients, 88 had tumor specimens available for analysis of PD-L1 expression. Seventeen of these 88 patients (19.3%) had a tumor proportion score (TPS) for PD-L1 of 50% or higher, 37 (42.0%) had a TPS of 1% to 49%, and 34 (38.6%) had a TPS less than 1%.
Univariable and Multivariable Analysis of Biomarkers for Survival Outcome
To identify peripheral blood biomarker candidates for nivolumab treatment, we examined six peripheral blood parameters measured before treatment initiation ( Table 2 ). Univariable Cox proportional hazard regression analysis of these factors revealed that an AEC of 150/mL or higher was associated with a significantly better PFS (HR ¼ 0.63, 95% CI: 0.42-0.95, p ¼ 0.03) and OS (HR ¼ 0.44, 95% CI: 0.23-0.84, p ¼ 0.01). An ALC of 1000/mL or higher also tended to be associated with a better PFS (p ¼ 0.09) and was significantly associated with a better OS (p ¼ 0.03). In contrast, a trend toward a worse PFS and OS was apparent in patients with an ANC Table 2 ). Given that variables identified as affecting outcome by univariable analysis might be covariates, we performed multivariable Cox proportional regression analysis with parameters found to have a P value less than 0.2 in the univariable analysis to identify independent factors related to the efficacy of nivolumab in terms of PFS and OS. Multivariable analysis in which age, ECOG performance status, smoking status, and mutational status (EML4-ALK and TKI-sensitive EGFR mutations) were included as covariates revealed that a high ALC (HR ¼ 0.55, 95% CI: 0.31-0.97, p ¼ 0.04) and a high AEC (HR ¼ 0.53, 95% CI: 0.31-0.91, p ¼ 0.02) were significantly associated with a better PFS, whereas a high ANC was significantly associated with a worse PFS (HR ¼ 3.97, 95% CI: 1.78-8.88, p ¼ 0.001) ( Table 3 ). In multivariable analysis of OS, the number of lines of treatment was also included as a covariate because it tends to influence OS. The associations of blood cell counts observed in multivariable analysis of PFS were also apparent in that of OS (for ANC, 
Multiparameter Model for Survival of Patients Receiving Nivolumab
We then analyzed outcome according to the number of favorable factors, including an ANC less than 7500/mL, ALC of 1000/mL or higher, and AEC of 150/mL or higher. None of the study patients lacked all three favorable factors at baseline. The 17 patients (12.7%) with only one favorable factor (group C) showed a significantly shorter PFS and OS than those who had all three (group A) or two (group B) favorable factors (P < 0.001) (Fig. 1A and B) . Multivariable analysis including clinically important covariates confirmed that the number of favorable factors was significantly related to PFS and OS (Table 4) . Moreover, the response rate increased according to the number of favorable factors, being 5.9%, 27.1%, and 43.5% in groups C, B, and A, respectively (Fig. 1C) .
Peripheral Blood Parameters Combined with PD-L1 Expression Level
Finally, the association between tumor PD-L1 expression and patient survival was evaluated in the study cohort. Patients with a PD-L1 TPS of 50% or higher experienced a significantly better PFS and tended to show a longer OS ( Fig. 2A and B) . Given that the PFS curve for a TPS less than 1% did not differ significantly from that for a TPS of 1% to 49%, survival analysis according to the number of favorable factors was Figure 1 . Kaplan-Meier analysis of progression-free survival (PFS) and overall survival (OS), as well as response rate for patients with nivolumab-treated NSCLC according to the number of favorable baseline factors (absolute neutrophil count <7500/mL, absolute lymphocyte count 1000/mL, and absolute eosinophil count 150/mL). PFS rate (A), OS rate (B), and response (complete or partial) rate according to the Response Evaluation Criteria in Solid Tumors (C) were determined for patients in groups A, B, and C (three, two, and one factors, respectively). p Values were calculated with the log-rank test (A and B) or with Fisher's exact test (C). CI, confidence interval; NA, not available.
performed for patients with a TPS of 50% or higher versus for those with a TPS less than 50%. A weak trend toward a better PFS (Fig. 2C) or OS (Fig. 2E) according to the number of favorable factors was apparent for patients with a TPS less than 50%. All patients whose tumors had a TPS of 50% or higher had at least two favorable factors ( Fig. 2D and F) . Kaplan-Meier curves of PFS and OS for patient subgroups with a TPS less than 1% or from 1% to 49% according to the number of favorable factors are shown in Supplementary Figure 3 .
Discussion
Expression of PD-L1 in tumor tissue is the bestestablished biomarker for treatment with antibodies to PD-1 or to PD-L1 in patients with advanced NSCLC. However, the identification of additional biomarkers is important because PD-L1 expression status in some patients is not associated with the efficacy of such treatment. The advantages of peripheral blood over tumor tissue as a source of biomarkers include ease of access and assay. Baseline counts of peripheral blood cells such as neutrophils, lymphocytes, and eosinophils and the ratio of neutrophils to lymphocytes have been found to be associated with outcome in patients with melanoma treated with ipilimumab [5] [6] [7] [16] [17] [18] or pembrolizumab. 9 Given the still-limited experience with ICIs in patients with NSCLC, however, potential blood biomarkers for these agents in lung cancer have remained unclear. As far as we are aware, our present study with 134 patients with NSCLC is the first to show that ANC, ALC, and AEC at treatment initiation are independent potential biomarkers for both PFS and OS in patients with NSCLC treated with nivolumab. Our data thus revealed that a high ALC (1000/mL), a high AEC (150/mL), and a low ANC (<7500/mL) were significantly associated with a better PFS and OS in patients with NSCLC.
Given that lymphocytes are thought to play a central role in the action of ICIs, the association between a high ALC and favorable clinical outcome may reflect the predicted mechanism of nivolumab action. Indeed, immunologic assessments from a phase I study of nivolumab are indicative of a redistribution of lymphocyte subsets from blood to tumor and tissue sites. 19 Although ALC may not take into account immune suppressive versus stimulatory interactions, a threshold ALC of 1000 cells/mL may reflect the underlying capacity of the immune system to be activated by nivolumab to an extent sufficient to mediate a clinically meaningful antitumor effect. In addition, recent studies have indicated that not only lymphocytes but also neutrophils 6 and eosinophils 15 may influence the outcome of ipilimumab therapy in patients with melanoma. Cells of the innate immune system might serve as accessory cells that contribute to tumor-specific T cell responses. Multiple mechanisms have been proposed for the immunosuppressive action of neutrophils. For instance, by producing cytokines such as transforming growth factor-b, C-C motif chemokine ligand 2, and C-C motif chemokine ligand 17, neutrophils are able to initiate and engage in complex cross talk with other immune cells, leading to the generation of an immunosuppressive environment. 20 With regard to eosinophils and cancer, in addition to potential direct effects of eosinophils on tumor growth, activated eosinophils play an important role in tumor rejection by modulating the tumor microenvironment and promoting the infiltration of tumor-specific CD8-positive T cells. 21 Given that the immune response is balanced by interactions between T cells and other regulatory cells, [21] [22] [23] [24] evaluating several biomarkers rather than focusing on just one might allow a better prediction of ICI efficacy as well as provide insight into the underlying biological mechanisms.
We here propose a combinatorial model for outcome of nivolumab treatment based on three baseline biomarkers. Simultaneous increase in both ALC and AEC and a reduced ANC were associated with a better clinical outcome for patients with NSCLC treated with nivolumab. Of note, patients with a high ALC and AEC as well as a low ANC (group A) showed a 77% risk reduction for disease progression and an 89% risk reduction for death compared with those with only one favorable factor (group C). Pembrolizumab is indicated for first-line (C and D) PFS rate for patients with a PD-L1 TPS less than 50% or 50% or higher, respectively, in groups A, B, and C (three, two, and one favorable factors, respectively). (E and F) OS rate for patients with a PD-L1 TPS less than 50% or 50% or higher, respectively, in groups A, B, and C. p Values were calculated with the log-rank test.
treatment of patients with NSCLC whose tumors have a high level of PD-L1 expression (a TPS of 50%) on the basis of the improvement in clinical outcome observed in this patient subpopulation. 11 Determination of PD-L1 expression has therefore been thought to select those patients likely to receive maximal benefit from pembrolizumab treatment. Our analysis also found that nivolumab treatment resulted in a better outcome in patients with a PD-L1 TPS of 50% or higher. However, given that some patients with a low level of PD-L1 expression (TPS <50%) also experience clinical benefit from ICIs, evaluation of PD-L1 expression in tumor tissue by immunohistochemistry fails to identify all individuals who might benefit from such treatment. To date, there are no established biomarkers for the identification of patients who are not likely to benefit from ICI treatment. As revealed by the limited efficacy of nivolumab in patients of group C in the present study, who showed a response rate of 5.9% and a median PFS of 55 days, the combination of ANC, ALC, and AEC may identify a subpopulation of patients who are not likely to benefit from nivolumab treatment. Given the limited study population, it was difficult to draw similar conclusions for subgroups of patients on the basis of level of PD-L1 expression. However, the number of favorable factors also tended to be associated with survival benefit in patients with a PD-L1 TPS less than 50%, with such individuals accounting for more than half of patients with NSCLC in the clinical setting.
There are several limitations to the present study. First, the study lacks a control group of patients who did not receive nivolumab. Although the study design might not allow establishment of whether ANC, ALC, and AEC are general prognostic markers or predictive markers of response to nivolumab, the improvement in PFS and the better response rate for patients with favorable values for these parameters are more likely related to the beneficial mode of action of the applied treatment than is the improvement in OS, which may be only prognostic. In spite of previous studies showing that an elevated neutrophil count and increased neutrophil-to-lymphocyte ratio are indicative of a poor prognosis in patients with advanced NSCLC, 25, 26 the association of the baseline biomarkers identified in the present study with both PFS and OS underlines their potential predictive role and potential clinical utility for daily oncology practice. Another limitation of our study is that the cutoff values and the multiparameter model require validation in additional patient populations and preferably in a prospective manner, given the retrospective nature of the present analysis and relatively small number of participating institutions.
In conclusion, our data suggest that ANC, ALC, and AEC are independent biomarkers for PFS and OS in patients with NSCLC treated with nivolumab. Furthermore, the combination of these three parameters allows the identification of patients who are more likely to benefit from nivolumab therapy in advance of its initiation. Given the routine nature of the assessment of these favorable peripheral blood factors at baseline, our model could be readily integrated into daily clinical practice. In addition, as far as we are aware, our study is the first to assess both peripheral blood parameters and tumor PD-L1 expression in patients with NSCLC treated with nivolumab. Although the sample size was too small to draw definitive conclusions regarding the combination of the three baseline blood biomarkers and tumor PD-L1 expression, the predictive value of this combination warrants further investigation in a larger cohort. Further evaluation of these factors will help to optimize disease management strategies by providing patients with the best-suited treatment, sparing them from unnecessary drug-related toxicities, and providing better costeffectiveness in the treatment of lung cancer.
